Welcome to our dedicated page for Procept Biorobotics SEC filings (Ticker: PRCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PROCEPT BioRobotics Corporation (PRCT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. PROCEPT BioRobotics is a surgical robotics company in urology, listed on The Nasdaq Global Market under the symbol PRCT, and its filings offer detailed information on business operations, financial performance, risk factors, and governance.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for discussions of revenue from AQUABEAM and HYDROS Robotic Systems, segment details such as U.S. and international revenue, gross margins, operating expenses, and liquidity. Current reports on Form 8-K include items such as quarterly financial results, changes to executive compensation arrangements, and other material events affecting the company.
Through this page, users can also track executive and director compensation arrangements and changes to severance or change-of-control agreements, as disclosed in 8-K exhibits. While insider transaction reports on Form 4 are not listed in the excerpts above, Stock Titan’s filings interface is designed to surface such ownership changes when available, alongside 10-K, 10-Q, and 8-K filings.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, helping readers quickly understand topics such as revenue trends, installed base growth, non-GAAP measures like Adjusted EBITDA, and risk factor highlights. Real-time updates from the SEC’s EDGAR system ensure that new PRCT filings appear promptly, allowing investors, analysts, and researchers to follow PROCEPT BioRobotics’ regulatory and financial reporting history in one place.
PROCEPT BioRobotics Corp ownership disclosure: The Vanguard Group filed an Amendment No. 4 to a Schedule 13G/A reporting 0 shares beneficially owned of Common Stock, representing 0%. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, causing certain Vanguard subsidiaries and divisions to report separately; Vanguard states those units pursue the same investment strategies previously used.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
PROCEPT BioRobotics Corp executive vice president and chief legal officer Alaleh Nouri reported selling a total of 5,363 shares of common stock in two open‑market transactions. The shares were sold at weighted average prices of $25.8193 for 3,031 shares and $26.1460 for 2,332 shares.
The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 4, 2025. After the transactions, Nouri directly holds 105,354 shares, indicating the sales represent a relatively small portion of her overall position.
Alalah Nouri filed a Form 144 notice proposing the sale of company common stock derived from RSU vesting. The filing lists proposed amounts of 2,820, 1,996 and 547 shares tied to RSU vesting dates in March 2026, and shows 3,243 shares sold on 03/10/2026.
PROCEPT BioRobotics Corp executive reports small share sale tied to tax withholding. EVP, Chief Legal Officer and Corporate Secretary Alaleh Nouri sold 304 shares of common stock at an average price of $28.1532 per share. According to the footnote, the sale was made solely to cover tax withholding obligations from the vesting of restricted stock units, rather than as a discretionary open-market transaction. After this sale, Nouri directly holds 110,717 shares of PROCEPT BioRobotics common stock, indicating the transaction is minor relative to her overall stake.
PROCEPT BioRobotics Corp EVP and CFO Kevin Waters reported a small insider transaction involving company common stock. On March 17, 2026, he sold 706 shares at an average price of $28.1532 per share. According to the footnote, these shares were sold specifically to cover tax withholding obligations tied to the vesting of Restricted Stock Units, making this a routine, compensation-related event rather than a discretionary sale. After the transaction, Waters still directly owns 151,558 shares of PROCEPT BioRobotics common stock.
PRCT reports an insider sale and a planned issuance of common stock. Alaleh Nouri sold 6,892 shares of Common Stock on 03/06/2026 for $163,353.49. The filing also lists 304 shares of Common Stock issued for compensation (restricted stock vesting) on 03/16/2026.
PRCT submitted a Form 144 notice reporting a proposed sale of Common stock tied to a restricted stock vesting event dated 03/16/2026. The filing also records a prior sale by Kevin Waters of 6,721 shares on 03/06/2026 for $159,300.47.
PROCEPT BioRobotics EVP, CLO and Corporate Secretary Alaleh Nouri sold 3,243 shares of common stock in open-market transactions. The sales on March 10, 2026 occurred at weighted average prices of $25.6037 and $26.7379 per share under a Rule 10b5-1 trading plan adopted on June 4, 2025. Following these transactions, Nouri directly holds 111,021 shares of PROCEPT BioRobotics common stock.
PROCEPT BioRobotics Corp director-linked entity Kestrel Fund, L.P. reported open-market purchases of 426,262 shares of common stock over several days. The buys occurred on March 5, 6 and 9, 2026 at weighted average prices generally between the low $20s and mid $20s per share, as detailed in price ranges in the footnotes. The filing also shows 35,152 shares held directly and 14,363 shares held indirectly by The 2:22 DNA Trust as of March 5, 2026. Antal Rohit Desai, a director and managing partner of CPMG, Inc., may be deemed to share voting and investment power over Kestrel Fund holdings but disclaims beneficial ownership except to the extent of any pecuniary interest.